Middle East and Africa Generic Injectables Market Report and Forecast 2024-2032

Middle East and Africa Generic Injectables Market Size

The Middle East and Africa generic injectables market was valued at USD 0.9 billion in 2023, driven by the growing demand for cost-effective healthcare solutions and growth in local generic manufacturing capabilities in the region. The market is expected to grow at a CAGR of 7.80% during the forecast period of 2024-2032, with the values likely to rise from USD 1 billion in 2024 to USD 1.9 billion by 2032. 

Middle East and Africa Generic Injectables Market Outlook

• The Middle Eastern and African countries are heavily investing in the healthcare and pharmaceutical sectors which directly impacts the production of low-cost generic injectable products.

• The rising innovations in formulations of faster-acting injectable generics in oncology and specialty therapeutic areas are poised to fuel the Middle East and Africa generic injectables market demand.

• One of the major market trends is the increase in public-private partnerships to accelerate the availability of affordable generic injectables in low-income countries.

Middle East and Africa Generic Injectables Market Analysis

Generic injectables are high-quality bioequivalent versions of expensive innovator injectables, typically marketed at a lower price. These pharmaceutical products are injected either by a healthcare worker or the patients themselves and are used in certain clinical settings such as cancer care, trauma, and surgery, due to their rapid onset of action and higher bioavailability. There is a growing focus on the development of novel formulations of these faster-acting generics in oncology and specialty therapeutic areas, which is influencing the global generic injectables market landscape. Further, several generic manufacturers are increasingly investing in expanding their generic injectable portfolio to meet the growing healthcare demand, which is expected to fuel the Middle East and Africa generic injectables market growth.

The Middle Eastern and African countries are heavily investing in the healthcare and pharmaceutical sectors which has substantially affected the market demand. Recent data reveals that the size of the pharmaceutical market in Saudi Arabia has witnessed a massive increase, with most of the national pharmaceutical industries focused on the production of generics. Additionally, local manufacturing of generic injectables was estimated to be 30% out of all dosage forms in the region.  This growth of local generic pharmaceutical manufacturing capabilities and capacities, supported by both public and private investments, is projected to boost the Middle East and Africa generic injectables market share.

One of the major market trends is the rise in strategic partnerships between public and private bodies to address global health challenges. For instance, in March 2023 , multinational pharmaceutical company GlaxoSmithKline (GSK plc) issued voluntary licenses to three companies (Aurobindo Pharma, Cipla, and Viatris) to manufacture generic versions of its HIV preventive medicine (injectable drug cabotegravir). This deal is likely to expedite market penetration of this injectable in lower-income countries. Further, Indian drugmaker Cipla reported plans to manufacture the generic injection in South Africa. Moreover, GSK also announced a public-private partnership with the Medicines Patent Pool (a United Nations-backed healthcare organization) in July 2022, to accelerate access to new HIV therapies in poor countries, with the introduction of its generic injectables expected by 2026.  Such licensing agreements indicate an emphasis on increasing access to cost-effective medications which is anticipated to elevate the market value in the forecast period.

Middle East and Africa Generic Injectables Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Leading Players in the Middle East and Africa Generic Injectables Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Pfizer Inc.

Pfizer has a strong presence in the sterile injectables industry, with a range of offerings in generic and branded products. To expand its market presence in the generic injectables sector, it acquired a leading manufacturer of injectable drugs and infusion technologies, Hospira, in 2015.

Baxter

A global leader in generic injectables, Baxter International Inc., is actively engaged in strategic mergers and acquisition activities to bolster the development of generic injectables in various therapeutic categories.

Hikma Pharmaceuticals PLC

This British multinational pharmaceutical company is known for its non-branded generic and in-licensed products. It is a leading supplier of injectable pharmaceuticals in the Middle East and North African countries and is focusing on expanding local manufacturing operations in the region.

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company, is a prominent player in the market. It specializes in developing generic formulations, including injectables, tablets, capsules, and topical creams across the major therapeutic areas.

Other players in the market include Viatris Inc., and Sanofi, among others.

Key Highlights of the Report

Middle East and Africa Generic Injectables Market Report Snapshots

Middle East and Africa Generic Injectables Market Size

Middle East and Africa Generic Injectables Market Analysis

Middle East and Africa Generic Injectables Companies